Acasti Pharma Files 8-K with Office and Contact Info

Ticker: GRCE · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1444192

Acasti Pharma INC. 8-K Filing Summary
FieldDetail
CompanyAcasti Pharma INC. (GRCE)
Form Type8-K
Filed DateJun 27, 2024
Risk Levellow
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-info, filing

Related Tickers: ACST

TL;DR

Acasti Pharma filed an 8-K on 6/27, updating its Princeton, NJ office address and phone number.

AI Summary

Acasti Pharma Inc. filed an 8-K on June 27, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540, and provides its telephone number as 818-839-4378. No specific financial transactions or material events were detailed in the provided text excerpt.

Why It Matters

This filing provides updated corporate information for Acasti Pharma Inc., including its principal executive office address and contact number, which is important for investors and stakeholders to have accurate company details.

Risk Assessment

Risk Level: low — The filing is primarily administrative, updating corporate contact information without disclosing new material financial events or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Acasti Pharma Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits', specifically updating the company's principal executive office address and contact information.

When was this 8-K filing submitted by Acasti Pharma Inc.?

This 8-K filing was submitted on June 27, 2024.

Where are Acasti Pharma Inc.'s principal executive offices located?

Acasti Pharma Inc.'s principal executive offices are located at 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540.

What is the telephone number listed for Acasti Pharma Inc. in this filing?

The telephone number listed for Acasti Pharma Inc. is 818-839-4378.

Does this filing disclose any new material financial events or transactions for Acasti Pharma Inc.?

Based on the provided text excerpt, this filing primarily serves to update corporate contact and location information and does not explicitly disclose new material financial events or transactions.

Filing Stats: 418 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-06-27 16:10:09

Filing Documents

01 Other Events

Item 8.01 Other Events. On June 27, 2024, the Company issued a press release announcing the Company's pivotal Phase 3 STRIVE-ON safety trial has exceeded the 50% enrollment milestone. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated June 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ACASTI PHARMA INC. Date: June 27, 2024 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing